This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Beyond the Abstracts
Pelvic Health & Reconstruction
Overactive Bladder
Beyond the Abstracts
Intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment: Women's perspective, "Beyond the Abstract," by Pooja Balchandra
July 28, 2014
Repeated botulinum toxin type A (Dysport®) injections for women with intractable detrusor overactivity, "Beyond the Abstract," by Angamuthu Arunkalaivanan
July 25, 2014
Urethral calibration for the treatment of women with overactive bladder syndrome, "Beyond the Abstract," by Chao H. Chen, MD; Renee Sato, MD; Grace Matsuura, MPH; and David Wei, MD
June 13, 2014
Defining response and non-response to treatment in patients with overactive bladder: A systematic review, "Beyond the Abstract," by Howard B. Goldman MD FACS, et al
June 12, 2014
Options for the treatment of bladder dysfunction in neurologic disease, "Beyond the Abstract," by Eliza Lamin, MD
May 30, 2014
The most bothersome lower urinary tract symptoms as reported by men and by women, "Beyond the Abstract," by Arnav Agarwal, Leyla Eryuzlu, Rufus Cartwright, and Kari A.O. Tikkinen
May 8, 2014
The anatomical basis of pelvic organ prolapse (POP) and site-specific ligament repair using the TFS system, "Beyond the Abstract," by Yuki Sekiguchi and Peter Petros
April 29, 2014
Management of lower urinary tract symptoms in children and adolescents with cerebral palsy using uroflowmetry, "Beyond the Abstract," by Fabricio Borges Carrerette, PhD
April 23, 2014
Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder, "Beyond the Abstract," by Cristian Sager, et al
March 7, 2014
InterStim lead wire placement with curved versus straight stylet: A randomized prospective crossover study, "Beyond the Abstract," by Stephanie A. Jacobs, MD
December 11, 2013
Validation of the Spanish version of the questionnaire "Benefit, Satisfaction and Willingness to Continue the Treatment" in patients with overactive bladder, "Beyond the Abstract," by Miguel A. Jiménez-Cidre
November 15, 2013
For women with overactive bladder syndrome, urinary ATP may be a dynamic biomarker of detrusor overactivity, "Beyond the Abstract," by Miguel Silva-Ramos and Paulo Correia-de-Sá
November 8, 2013
Non-alcoholic fatty liver disease is associated with overactive bladder in women and with benign prostate hyperplasia in men, "Beyond the Abstract," by Hakkı Uzun, MD
October 10, 2013
A pelvic floor fitness program for older women with urinary symptoms, "Beyond the Abstract," by Sheila Dugan, MD, Missy Lavender, MBA, Jennifer Hebert-Beirne, PhD, MPH, and Linda Brubaker, MD, MS
August 15, 2013
NGF in bladder - A drug target for local treatment, "Beyond the Abstract," by Pradeep Tyagi, PhD
August 6, 2013
Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 36 month efficacy outcomes, "Beyond the Abstract," by Kenneth M. Peters, MD
July 31, 2013
Biomarkers in overactive bladder, "Beyond the Abstract," by G. Alessandro Digesu, MD, et al
July 29, 2013
"Beyond the Abstract," Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder, by Eric Rovner, MD and Nancy Martin, MD, PharmD
April 23, 2013
Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin, "Beyond the Abstract," by Naoki Aizawa, Yukio Homma, and Yasuhiko Igawa
April 16, 2013
Urinary neurotrophic factors in healthy individuals and patients with overactive bladder, "Beyond the Abstract," by Tiago Antunes-Lopes, MD
April 9, 2013
Page 3 of 5
Start
Prev
1
2
3
4
5
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free